Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide

被引：13
|
作者：
Kapitza, Christoph [1 ]
Zdravkovic, Milan [2 ]
Zijlstra, Eric [1 ]
Segel, Stine [2 ]
Heise, Tim [1 ]
Flint, Anne [2 ]
机构：
[1] Profil Inst Stoffwechselforsch GmbH, D-41460 Neuss, Germany
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 06期
关键词：
Type 2 diabetes mellitus; glucagon-like peptide-1; incretin; exenatide; DPP-IV; GLUCAGON-LIKE PEPTIDE-1; ABSORPTION; INSULIN; NN2211; CELL; PHARMACODYNAMICS; TOLERABILITY; SAFETY;
D O I：
10.1177/0091270010374474
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：951 / 955
页数：5
相关论文
共 50 条
  • [41] The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
    Christoph Kapitza
    Milan Zdravkovic
    Charlotte Hindsberger
    Anne Flint
    Advances in Therapy, 2011, 28 : 650 - 660
  • [42] The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
    Kapitza, Christoph
    Zdravkovic, Milan
    Hindsberger, Charlotte
    Flint, Anne
    ADVANCES IN THERAPY, 2011, 28 (08) : 650 - 660
  • [43] Liraglutide, a Once-Daily Human GLP-1 Analog, Lowers Systolic Blood Pressure (SBP) Independently of Concomitant Antihypertensive Treatment
    Fonseca, Vivian
    Plutzky, Jorge
    Montanya, Eduard
    Colagiuri, Stephen
    Hansen, Charlotte
    Falahati, Ali
    Devries, J. Hans
    DIABETES, 2010, 59 : A79 - A79
  • [44] Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)
    Kaku, Kohei
    Rasmussen, Mads
    Katayama, Yasuyuki
    Seino, Yutaka
    DIABETES, 2009, 58 : A144 - A144
  • [45] Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2013, 37 : 322 - 322
  • [46] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [47] The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms
    Shimoda, M.
    Kanda, Y.
    Tawaramoto, K.
    Hashiramoto, M.
    Matsuki, M.
    Kaku, K.
    DIABETOLOGIA, 2008, 51 : S210 - S210
  • [48] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
    Plutzky, J.
    Garber, A. J.
    Falahati, A.
    Toft, A. D.
    Poulter, N. R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
  • [49] Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide
    Flint, Anne
    Nazzal, Khalil
    Jagielski, Pawel
    Segel, Stine
    Zdravkovic, Milan
    DIABETES, 2007, 56 : A145 - A145
  • [50] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    Plutzky, J.
    Garber, A.
    Toft, A. D.
    Poulter, N. R.
    DIABETOLOGIA, 2009, 52 : S299 - S300
12345